bp(GO:locomotion)

Entity

Name

locomotion

Namespace

go

Namespace Version

20180921

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns

Both VU0152100 and VU0152099 effectively reversed amphetamine-induced hyperlocomotion, demonstrating antipsychotic-like activity in preclinical models. PubMed:24511233

The locomotor behavior during the NOR habituation phase was measured by the total distance traveled: APP-WT showed higher locomotor activity compared with GFP-WT (p = 0.0027; Fig. 2F) PubMed:27522251

General characterization showed that the knockout mice as compared to their wild-type littermates show no changes in body weight, have slight increases in body temperature (Figures S3A and S3B), and exhibit significantly enhanced locomotor activity (Figures S2A and S2B) PubMed:28445721

The NACHO knockouts showed increased total number of arm entries in the Y-maze, which fits with their enhanced locomotor activity (Figure S2F) PubMed:28445721

4OH-GTS-21 had no effect on the latency to enter the dark chamber during avoidance training (Fig. 1 ) or on swim speed in the Morris water task (data not shown), indicating that it had no discernible effect on locomotor function PubMed:17640819

Transgenic mouse models of AD overexpressing Aβ peptides generally show greater locomotor activity and disinhibition in the elevated plus maze compared to non-transgenic mice, suggest- ing hyperactivity and a lower level of anxiety [28–30]. PubMed:26010758

Interestingly, the hyper- active behavior of Tg PS1/APPswe mice was suppressed with the anatabine treatment at a dos- age of 20 mg/Kg/Day (Fig 2B and 2C). PubMed:26010758

We supplemented the growth medium of syn- chronized L1 larvae (pro-aggregant strain) with 25 m M MB and measured their locomotion speed as day 1 young adults. This treatment led to 15% amelioration of locomotion (Sup- plementary Material, Fig. S6A). PubMed:22611162

We then applied, in the 96-well liquid culture format, the two most promising hit compounds obtained in a mammalian cell model of Tau toxicity (57), namely the phenylthiazolyl- hydrazide derivatives Bsc3094 and bb14, and observed a similar amelioration effect in locomotion (Supplementary Ma- terial, Fig. S6B). PubMed:22611162

At 100 m M , we observed improved locomotion of treated animals. These animals moved approximately 1.6 times faster than DMSO-treated controls (Fig. 9A). PubMed:22611162

We then applied, in the 96-well liquid culture format, the two most promising hit compounds obtained in a mammalian cell model of Tau toxicity (57), namely the phenylthiazolyl- hydrazide derivatives Bsc3094 and bb14, and observed a similar amelioration effect in locomotion (Supplementary Ma- terial, Fig. S6B). PubMed:22611162

The motility of the pro-aggregant worms was considerably enhanced upon apply- ing RNAi against F3DK280 (speed ¼ 70.7 + 17 mm/s for RNAi-treated versus 40.3 + 17 for control), whereas the anti- aggregant worms showed no difference upon treatment (Sup- plementary Material, Fig. S1C). PubMed:22611162

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

The antipsychotic drug azaperone shows neuroprotective effects, improves locomotion, reduces the insoluble tau, and partially abates the neurodegeneration in this tauopathy model (104). PubMed:29191965

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

In a recent study, the antiepileptic drug ethosuximide increased the lifespan and partially corrected the Unc phenotype in TauV337M worms with the effect dependent on the insulin signaling pathway (106). PubMed:29191965

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

Indeed, 2 of the candidates identified in an RNAi screen that worsened the Unc phenotype in the TauV337M worm, called enhancers of tauopathy, were postsynaptic (80). PubMed:29191965

Indeed, 2 of the candidates identified in an RNAi screen that worsened the Unc phenotype in the TauV337M worm, called enhancers of tauopathy, were postsynaptic (80). PubMed:29191965

Loss of bas-1 function improved the motor function, reduced insoluble tau and its phosphorylation and ameliorated the tau-induced neurodegeneration without increasing the longevity in TauV337M worms PubMed:29191965

Eliminating sut-2 resulted in partial recovery of Unc phenotype, less neurodegeneration and reduction of insoluble tau in the TauV337M worm; whereas sut-2 overexpression exacerbated the pathology PubMed:29191965

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

The transgenic lines exhibited a progressive age-associated Unc phenotype, with or without phospho-mimicking mutations PubMed:29191965

The transgenic lines exhibited a progressive age-associated Unc phenotype, with or without phospho-mimicking mutations PubMed:29191965

Intraneuronal iron accumulation, neuronal loss in the substantia nigra and a severe decline in locomotor functions were observed in 12‑month-old tau-knockoutmice PubMed:26631930

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965